The number of patients with interruptions and dose reduction as a result of AEs in HER2-zero breast cancer were 15(62.5%) and 4(16.7%), while in HER2-low breast cancer were 13(61.9%) and 4(19.0%), respectively. The gene discussed is ERBB2; the disease is breast cancer.